« Return to News | Drug Sponsors

Islet Sciences to acquire DiaKine Therapeutics

Friday, March 2, 2012 06:00 AM

Islet Sciences, a biotechnology company specializing in transplantation therapy for patients with diabetes, will acquire Charlottesville, Va.-based biopharmaceutical company DiaKine Therapeutics, which commercializes novel immune modulators for the treatment of diabetes and related complications.

A primary focus of DiaKine's R&D is its next generation of orally bioavailable immune modulators, which have an improved spectrum of action to Lisofylline—its most clinically advanced drug. Several lead compounds have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications.

"DiaKine's drugs have the potential to reshape the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease,” said John Steel, chairman and CEO of Islet Sciences. “Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes, which we believe has a total addressable market of approximately $13 billion. We believe this acquisition will position us to capitalize on the exciting opportunities emerging in our industry."

Islet Sciences agreed to issue DiaKine shareholders an aggregate of 200,000 shares of its newly designated shares of Series C preferred stock in exchange for all issued and outstanding shares of DiaKine.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.